Trial Profile
RETART.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2012
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Fluvastatin (Primary)
- Indications Atherosclerosis; Coronary artery disease; Dyslipidaemias
- Focus Biomarker; Pharmacodynamics
- Acronyms RETART
- 21 May 2012 Actual end date changed from 1 Mar 2008 to 31 Mar 2009 as reported by Chinese Clinical Trial Register.
- 02 Oct 2009 New trial record